GAMMA Investing LLC raised its stake in Healthcare Realty Trust Incorporated (NYSE:HR - Free Report) by 1,650.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 138,022 shares of the real estate investment trust's stock after purchasing an additional 130,137 shares during the quarter. GAMMA Investing LLC's holdings in Healthcare Realty Trust were worth $23,330,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in HR. Wealth Enhancement Advisory Services LLC lifted its stake in Healthcare Realty Trust by 21.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 53,501 shares of the real estate investment trust's stock valued at $907,000 after purchasing an additional 9,467 shares during the last quarter. Comprehensive Money Management Services LLC bought a new stake in Healthcare Realty Trust in the fourth quarter valued at approximately $290,000. Employees Retirement System of Texas acquired a new stake in shares of Healthcare Realty Trust in the fourth quarter valued at approximately $3,390,000. AlphaCore Capital LLC acquired a new stake in shares of Healthcare Realty Trust in the fourth quarter valued at approximately $375,000. Finally, Mackenzie Financial Corp boosted its stake in shares of Healthcare Realty Trust by 234.9% during the 4th quarter. Mackenzie Financial Corp now owns 56,987 shares of the real estate investment trust's stock worth $966,000 after acquiring an additional 39,969 shares during the period.
Insider Buying and Selling at Healthcare Realty Trust
In other news, Director Thomas N. Bohjalian acquired 2,500 shares of the stock in a transaction on Tuesday, May 13th. The stock was acquired at an average cost of $14.71 per share, for a total transaction of $36,775.00. Following the completion of the transaction, the director now directly owns 56,502 shares in the company, valued at approximately $831,144.42. This trade represents a 4.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.37% of the company's stock.
Healthcare Realty Trust Price Performance
NYSE HR traded up $0.28 on Friday, reaching $14.46. The stock had a trading volume of 5,876,829 shares, compared to its average volume of 3,148,391. The company has a market cap of $5.08 billion, a P/E ratio of -8.12 and a beta of 0.92. The firm has a fifty day moving average of $15.24 and a two-hundred day moving average of $16.34. Healthcare Realty Trust Incorporated has a 1-year low of $14.09 and a 1-year high of $18.90.
Healthcare Realty Trust (NYSE:HR - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The real estate investment trust reported $0.39 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.39. Healthcare Realty Trust had a negative return on equity of 11.20% and a negative net margin of 51.60%. The business had revenue of $288.86 million during the quarter, compared to analysts' expectations of $297.39 million. During the same period in the previous year, the company posted $0.39 earnings per share. The firm's revenue for the quarter was down 9.2% compared to the same quarter last year. Research analysts predict that Healthcare Realty Trust Incorporated will post 1.59 EPS for the current fiscal year.
Healthcare Realty Trust Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, May 23rd. Shareholders of record on Monday, May 12th were paid a dividend of $0.31 per share. The ex-dividend date was Monday, May 12th. This represents a $1.24 dividend on an annualized basis and a yield of 8.58%. Healthcare Realty Trust's payout ratio is -113.76%.
Analyst Ratings Changes
A number of research firms recently weighed in on HR. Scotiabank dropped their price target on Healthcare Realty Trust from $18.00 to $17.00 and set a "sector perform" rating on the stock in a research note on Tuesday, February 25th. Wedbush dropped their price objective on shares of Healthcare Realty Trust from $18.00 to $16.00 and set a "neutral" rating on the stock in a research report on Monday, May 5th. Wells Fargo & Company cut their target price on shares of Healthcare Realty Trust from $16.00 to $15.00 and set an "underweight" rating for the company in a research note on Monday. Finally, Wall Street Zen lowered shares of Healthcare Realty Trust from a "hold" rating to a "sell" rating in a research note on Saturday, May 31st. Two investment analysts have rated the stock with a sell rating and four have given a hold rating to the stock. Based on data from MarketBeat.com, Healthcare Realty Trust currently has an average rating of "Hold" and an average target price of $16.80.
Get Our Latest Report on Healthcare Realty Trust
About Healthcare Realty Trust
(
Free Report)
Healthcare Realty Trust, Inc provides real estate investment services. It owns, leases, manages, acquires, finances, develops, and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States of America. The company was founded by David R.
Read More

Before you consider Healthcare Realty Trust, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Healthcare Realty Trust wasn't on the list.
While Healthcare Realty Trust currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.